Table 3.
Multiple Cox regression analysis of specified immunoreactivity scores in primary tumor biopsies, in relation to cancer-specific survival after androgen-deprivation therapy (ADT).
| Clinical Variables | HR (95% CI) | P |
|---|---|---|
| Age at diagnosis (yrs.) | 1.0 (1.0–1.1) | 0.066 |
| Serum PSA at diagnosis (ng/mL) | 1.1 (1.0–1.2) | 0.026 |
| ISUP grade at diagnosis | 1.0 (0.78–1.4) | 0.78 |
| Combinatory Ki67, PSA score a | ||
| Low Ki67, high PSA, n = 26 | ref. | |
| Others, n = 35 | 2.9 (1.6–5.3) | 0.00028 |
| High Ki67, low PSA, n = 31 | 2.5 (1.3–4.8) | 0.0065 |
| AR in stroma cells b | ||
| Q1, n = 23 | ref. | |
| Q2–3, n = 47 | 0.46 (0.25–0.86) | 0.014 |
| Q4, n = 22 | 0.37 (0.18–0.74) | 0.0050 |
a A combinatory immunoreactivity score for the marker of proliferation Ki67 and prostate specific antigen (PSA) constructed based on the median values (13% and 8%, respectively) stratified primary tumors into 3 groups: “low Ki67, high PSA”, “high Ki67, low PSA”, and “others”. b The androgen receptor (AR) score dichotomized based on quartiles (Q1, Q2–3, Q4; cut-offs 10 and 27%).